Answer

IFF Scent recovery: drivers, H2 evolution for Fine Fragrance vs. Consumer Fragrance, and R&D plan to support 2027

1) What are the drivers of Scent’s recovery?

A. Improved underlying momentum across the Scent portfolio (sales + profitability)

In Q2 2026, the Scent segment delivered sales of $665 million (+8%), with performance driven by double-digit growth in Fragrance Ingredients and a high single-digit increase in Consumer Fragrance, while Fine Fragrance grew low single digits (inclusive of Middle East impact). ¹
Scent profitability improved, with EBITDA growing 5% to $134 million, and management attributes this mainly to volume growth and productivity gains. ¹

B. Fine Fragrance recovery supported by active management of Middle East volatility and “tough comps” fade

Management notes that the team “did a very good job at managing the challenges in the Middle East” and that Fine Fragrance finished slightly positive despite expectations of mid-single-digit decline entering the quarter. ²
The recovery profile is tied to calendar effects: Q3 is expected to be softer, in part because Q3 last year included a ~+20% Fine Fragrance growth comp; then recovery is expected to become more visible in Q4. ²

C. Fragrance Ingredients strength as a near-term engine (but expected to normalize)

Q2 strength in Scent was strongly influenced by Fragrance Ingredients, where management cited growth north of 20% and explicitly described that some of the outperformance reflects a favorable year-over-year delta versus a down ~10% or more prior year period, but also strategic use of the synthetics portfolio to capture more sales amid macroeconomic conditions (including supply chain disruptions and higher Brent crude prices). ²
Looking ahead, management expects Fragrance Ingredients to normalize: specifically, they say the growth rate will shift back toward higher value-added ingredients versus traditional synthetics, and they frame this as a shift “underway” that will take more time. ³

D. R&D pipeline reset and go-to-market rebuild (capability and execution)

Management describes a turnaround in R&D capability: “2.5 years ago was not what it should have been,” but today they claim a “very strong R&D capability,” including a great R&D team, leading-edge new Fine Fragrances and Consumer Fragrances, and a strong pipeline of molecules and delivery systems. ⁴
They also emphasize rebuilding the R&D capability and go-to-market approach with customers to enable market share gains in Consumer Fragrance. ³

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Fine Fragrance (mid-single-digit H2 growth; Q3 softer, Q4 stronger)

Management’s framing for Fine Fragrance is that it will be “a little bit softer in Q3” but “a stronger Q4,” yielding an H2 run-rate in the mid-single-digit range (second half basis). ³
They link the softer period to comps and volatility: Middle East crisis continues, they factor softer Q3, note the ~20% YOY growth comp in Q3 last year, and then expect recovery as they get to Q4. ²

Consumer Fragrance (low single-digit H2; normalization after a strong Q2)

For Consumer Fragrance, management expects it to be in the low single-digit range in H2. ³
They cite that Q2 was a “really good Q2” at a high single-digit number, but they expect normalization going forward to low single-digit. ³
The operational mechanism emphasized is rebuilding R&D and go-to-market execution to drive market share gains. ³

Cross-current: Ingredients normalization may create pressure, but recovery trajectory remains intact

While your question targets Fine Fragrance vs. Consumer Fragrance, Scent’s second-half evolution also reflects the broader ingredients backdrop: management says Fragrance Ingredients was very strong in Q2, expects it to normalize going forward, and indicates it will be slightly under pressure on a year-over-year basis (while still pointing to competitive positioning improvements over time). ³
This matters because the Scent segment’s overall reported growth has benefited from Fragrance Ingredients (e.g., double-digit growth in Q2). ¹

3) Plan for R&D to support 2027

What management says the R&D state will be by now (the foundation)

Management is explicit that the R&D capability has improved materially over the last ~2.5 years: they cite a stronger R&D capability, great perfumers developing leading-edge new Fine Fragrances and Consumer Fragrances, and a great pipeline of molecules and delivery systems. ⁴

What R&D is intended to accomplish (growth + share gains into 2027)

For Consumer Fragrance, management ties recovery/forward evolution to R&D plus commercial execution: rebuilding R&D capability and the go-to-market approach with customers with the aim of driving market share gains. ³

Timing signals: ingredients shift is underway now; competitive position improves “next year and the year after”

While the excerpt speaks most directly about Fragrance Ingredients rather than Fine/Consumer R&D specifically, management’s timing is instructive for what “support 2027” means: they state the shift to higher-value natural products is underway, will take more time, and that they believe they will have “a really strong competitive position” as we go into next year and the year after. ³
Additionally, they emphasize investment/innovation as an important pillar for the transformed portfolio going forward, tied to continued reinvestment in R&D (they cite R&D spend as a % of sales in an 8%–9% range). ⁵

Net: R&D plan is positioned as capability + pipeline + customer execution, not a one-quarter fix

The evidence from the excerpts is that management’s plan is to (1) maintain the improved R&D pipeline and perfumer output, ⁴ (2) leverage it through customer-facing go-to-market rebuilding to win/expand share (especially in Consumer Fragrance), ³ and (3) sustain investment levels to underpin mid-term improvements extending into 2027 and beyond, consistent with their emphasis on innovation and reinvestment. ⁵

Bottom line synthesis

Drivers of recovery: Scent’s rebound is supported by (a) strong Q2 segment growth and margin improvement driven by volume/productivity, ¹ (b) active Fine Fragrance management of Middle East-related volatility with a Q3 soft / Q4 recovery pattern, ² (c) Fragrance Ingredients strength in Q2 that is expected to normalize as the business shifts back toward higher value-added ingredients, ³² and (d) a re-established R&D engine with a strong pipeline and customer go-to-market execution. ³⁴
Second-half evolution: Fine Fragrance is expected to be softer in Q3 and stronger in Q4, landing in mid-single-digit H2 growth, ³² while Consumer Fragrance is expected to normalize from Q2’s high-single-digit run to low-single-digit H2 growth. ³
R&D plan for 2027: management’s plan rests on the already-improving R&D capability/pipeline and the intent to sustain customer-facing execution (notably for Consumer Fragrance) while maintaining reinvestment levels to support future competitive positioning. ³⁴⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

Keep Reading

IFF Scent Recovery Driven by R&D Strength and Market Share Gains

IFF explains that Scent's recovery rests on rebuilding the R&D engine, expanding the pipeline, and regaining market share, with Fine Fragrance soft in Q3 but improving in Q4, and Consumer Fragrance returning to low single-digit growth in 2H 2026. The R&D program is positioned to support a stronger 2027 earnings framework, including a shift to higher-value ingredients.

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management says is driving the turnaround)
- Rebalanced Scent “system”: R&D investment + regain market share
- R&D pipeline improvement after being “behind” earlier
- Fine Fragrance: volatility/uncertainty in the Middle East is being actively managed, not ignored
- Fragrance Ingredients: strong Q2 performance acts as an important near-term engine, but is expected to normalize
- Business momentum already visible in Scent’s top-line and profitability
How Fine Fragrance and Consumer Fragrance are expected to evolve in 2H (Q3–Q4 2026)
- Fine Fragrance (2H): softer in Q3, stronger in Q4; mid-single-digit growth on a 2H basis
- Consumer Fragrance (2H): low single-digit normalization; Q2 strength expected to normalize going forward
- Fragrance Ingredients (important context for Scent recovery): normalizing after very strong Q2
Plan for R&D to support 2027 (what’s happening now, and how it’s positioned for the later years)
- Strengthened R&D capability + pipeline of molecules and delivery systems
- R&D is directly linked to commercial execution and market share gains
- R&D timing: ingredient/product strategy benefits are expected to appear into 2027 and the year after
- Management stance: progress made, but not “satisfied”—continued reinvestment to sustain innovation
- Innovation as a core reinforcement mechanism for the broader Remainco strategy (supporting 2027 earnings quality)
Bottom line synthesis

Keep Reading

IFF Scent Recovery Driven by R&D Strength and Market Share Gains

Sources used

Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?

Answer outline

Drivers of Scent’s recovery (what management says is driving the turnaround)
- Rebalanced Scent “system”: R&D investment + regain market share
- R&D pipeline improvement after being “behind” earlier
- Fine Fragrance: volatility/uncertainty in the Middle East is being actively managed, not ignored
- Fragrance Ingredients: strong Q2 performance acts as an important near-term engine, but is expected to normalize
- Business momentum already visible in Scent’s top-line and profitability
How Fine Fragrance and Consumer Fragrance are expected to evolve in 2H (Q3–Q4 2026)
- Fine Fragrance (2H): softer in Q3, stronger in Q4; mid-single-digit growth on a 2H basis
- Consumer Fragrance (2H): low single-digit normalization; Q2 strength expected to normalize going forward
- Fragrance Ingredients (important context for Scent recovery): normalizing after very strong Q2
Plan for R&D to support 2027 (what’s happening now, and how it’s positioned for the later years)
- Strengthened R&D capability + pipeline of molecules and delivery systems
- R&D is directly linked to commercial execution and market share gains
- R&D timing: ingredient/product strategy benefits are expected to appear into 2027 and the year after
- Management stance: progress made, but not “satisfied”—continued reinvestment to sustain innovation
- Innovation as a core reinforcement mechanism for the broader Remainco strategy (supporting 2027 earnings quality)
Bottom line synthesis

IFF Scent Recovery Gains Momentum; H2 Outlook and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery: drivers, H2 evolution for Fine Fragrance vs. Consumer Fragrance, and R&D plan to support 2027

1) What are the drivers of Scent’s recovery?

A. Improved underlying momentum across the Scent portfolio (sales + profitability)

B. Fine Fragrance recovery supported by active management of Middle East volatility and “tough comps” fade

C. Fragrance Ingredients strength as a near-term engine (but expected to normalize)

D. R&D pipeline reset and go-to-market rebuild (capability and execution)

2) How will Fine Fragrance and Consumer Fragrance evolve in the second half?

Fine Fragrance (mid-single-digit H2 growth; Q3 softer, Q4 stronger)

Consumer Fragrance (low single-digit H2; normalization after a strong Q2)

Cross-current: Ingredients normalization may create pressure, but recovery trajectory remains intact

3) Plan for R&D to support 2027

What management says the R&D state will be by now (the foundation)

What R&D is intended to accomplish (growth + share gains into 2027)

Timing signals: ingredients shift is underway now; competitive position improves “next year and the year after”

Net: R&D plan is positioned as capability + pipeline + customer execution, not a one-quarter fix

Bottom line synthesis

References

Keep Reading

IFF Scent Recovery Driven by R&D Strength and Market Share Gains

Keep Reading

Keep Reading

IFF Scent Recovery Driven by R&D Strength and Market Share Gains

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Sets Capex Target at 5-6% of Sales Post-Divestiture to Fund High-Return Initiatives

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Q2 Strength, R&D Push, and 2027 Plan

IFF Scent Recovery Driven by R&D, 2H 2026 Outlook and 2027 Plan

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead

IFF Scent Recovery Driven by R&D Rebuild, H2 Outlook, and 2027 Plan

IFF Scent Recovery Gains Momentum as R&D Engine Strengthens for 2027 Plan